Anticoagulation, bleeding and blood transfusion practices in Australasian cardiac surgical practice

Anaesthesia and Intensive Care

Volumn 35, Issue 5, 2007, Pages 760-768

  Daly, D J ^a   Myles, P S ^f   Smith, J A ^b,g,h   Knight, J L ^d,i   Clavisi, O ^j   Bain, D L ^a   Glew, R ^e   Gibbs, N M ^c   Merry, A F ^k  

^a ALFRED HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f MONASH UNIVERSITY   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h Australasian Society of Cardiac and Thoracic Surgeons   (Australia)

ⁱ FLINDERS UNIVERSITY   (Australia)

^j Australia New Zealand College of Anaesthetists   (Australia)

^k UNIVERSITY OF AUCKLAND   (New Zealand)

more..

Author keywords

Anticoagulation; Antifibrinolytic; Antiplatelet; Bleeding; Blood transfusion; Red cells

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEMOGLOBIN;

ADULT; AGED; ANESTHESIA; ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; ERYTHROCYTE; FEMALE; HEALTH SURVEY; HEART SURGERY; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; REVIEW;

EID: 35348895731     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0703500516     Document Type: Review

References (28)

1. Nalysnyk L, Fahrbach K, Reynolds MW, Zhao SZ, Ross S. Adverse events in coronary artery bypass graft (CABG) trials: a systematic review and analysis. Heart 2003; 89:767-772.
2. Myles PS, Hunt JO, Fletcher H, Watts J, Bain D, Silvers A et al. Remifentanil, fentanyl, and cardiac surgery: a double-blinded, randomized, controlled trial of costs and outcomes. Anesth Analg 2002; 95:805-812.
3. Taylor GJ, Mikell FL, Moses HW, Dove JT, Katholi RE, Malik SA et al. Determinants of hospital charges for coronary artery bypass surgery: the ecomonic consequences of postoperative complications. Am J Cardiol 1990; 65:309-313.
4. Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogenic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma 2003; 54:908-914.
5. Chelemer SB, Prato BS, Cox PM, O'Connor GT, Morton JR. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg 2002; 73:138-142.
6. Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006; 34:1608-1616.
7. Cosgrove DM 3rd, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992; 54:1031-1036.
8. Loop FD, Lytle BW, Cosgrove DM, Mahfood S, McHenry MC, Goormastic M et al. J. Maxwell Chamberlain memorial paper. Sternal wound complications after isolated coronary artery bypass grafting: early and late mortality, morbidity, and cost of care. Ann Thorac Surg 1990; 49:179-186.
9. Habib RH, Zacharias A, Schwann TA, Riordan CJ, Engoren M, Durham SJ et al. Role of hemodilutional anemia and transfusion during cardiopulmonary bypass in renal injury after coronary revascularization: implications on operative outcome. Crit Care Med 2005; 33:1749-1756.
10. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83:S27-86.
11. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S et al. Platelet transfusions during coronary artery surgery are associated with serious adverse outcomes. Transfusion 2004; 44:1143-1148.
12. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409-417.
13. Hébert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001; 29:227-234.
14. van de Watering LM, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97:562-568.
15. Bilgin YM, van de Watering LM, Eijsman L, Versteegh MI, Brand R, van Oers MH et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004; 109:2755-2760.
16. Taggart D, Siddiqui A, Wheatly DJ. Low-dose preoperative aspirin therapy, postoperative blood loss, and transfusion requirements. Ann Thorac Surg 1990; 50:424-428.
17. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
18. Belisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996; 62:1908-1917.
19. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40:231-237.
20. Alderman EL, Levy JH, Rich JB, Nili M, Vidne B, Schaff H et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicentre Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116:716-730.
21. Iaupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. Anesth Analg 1997; 85:1258-1267.
22. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briët E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354:1940-1947.
23. Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001; 1:CD001886.
24. Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353-365.
25. Datta M. You cannot exclude the explanation you have not considered. Lancet 1993; 342:345-347.
26. Hutton B, Fergusson D, Tinmouth A, McIntyre L, Kmetic A, Hébert PC. Transfusion rates vary significantly amongst Canadian medical centres. Can J Anaesth 2005; 52:581-590.
27. Parr KG, Patel MA, Dekker R, Levin R, Glynn R, Avorn J et al. Multivariate predictors of blood product use in cardiac surgery. J Cardiothorac Vasc Anesth 2003; 17:176-181.
28. Despotis GJ, Filos KS, Zoys TN, Hogue CW, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82:13-21.